Outcomes and predictors of survival in blast phase myeloproliferative neoplasms

G Lancman, A Brunner, R Hoffman, J Mascarenhas… - Leukemia research, 2018 - Elsevier
We retrospectively reviewed treatment outcomes for 57 patients with myeloproliferative
neoplasms in blast phase (MPN-BP). The median overall survival (OS) of the entire cohort
was 5.8 months. For patients receiving induction therapy, 67% achieved a complete
response (CR) and 75% received stem cell transplantation (SCT). Median OS for all
transplanted patients (n= 19) was not reached after a median follow-up of 19.2 months
compared with 3.8 months in non-transplanted patients (p< 0.0001); patients who did not …